Status:
COMPLETED
Corneal Collagen Cross-linking With Hypotonic Riboflavin in Corneas Thinner Than 400 Microns
Lead Sponsor:
Moorfields Eye Hospital NHS Foundation Trust
Collaborating Sponsors:
Peschke Meditrade, GmbH
Conditions:
Keratoconus
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Corneal ectasia is a relative weakness in the structure of the cornea, which produces a progressive change in its shape which results in visual distortion. It is known that collagen cross-linking in t...
Detailed Description
When cross-linking corneas of \> 400 microns, riboflavin in a solution with high molecular weight dextran T500 is used to prevent corneal swelling during the administration of the drops and the UV tre...
Eligibility Criteria
Inclusion
- Keratoconus
- Corneas thinner than 400 microns, but thicker than 250 microns
Exclusion
- Evidence of other corneal disease in the eye to be treated (e.g., Herpes simplex keratitis)
- Women who are pregnant or nursing at the time of the initial treatment
Key Trial Info
Start Date :
April 22 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 22 2010
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00890266
Start Date
April 22 2009
End Date
April 22 2010
Last Update
April 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Moorfields Eye Department at St George's Hospital
London, Greater London, United Kingdom, SW17 0QT